ES2535639T3 - Células y mamíferos no humanos modificados genéticamente - Google Patents

Células y mamíferos no humanos modificados genéticamente Download PDF

Info

Publication number
ES2535639T3
ES2535639T3 ES05748982.5T ES05748982T ES2535639T3 ES 2535639 T3 ES2535639 T3 ES 2535639T3 ES 05748982 T ES05748982 T ES 05748982T ES 2535639 T3 ES2535639 T3 ES 2535639T3
Authority
ES
Spain
Prior art keywords
masp
human
antibodies
antibody
map19
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05748982.5T
Other languages
English (en)
Spanish (es)
Inventor
Teizo Fujita
Hans-Wilhelm Schwaeble
Cordula Margaret Stover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leicester
Original Assignee
University of Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leicester filed Critical University of Leicester
Application granted granted Critical
Publication of ES2535639T3 publication Critical patent/ES2535639T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES05748982.5T 2004-06-10 2005-06-08 Células y mamíferos no humanos modificados genéticamente Expired - Lifetime ES2535639T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0412966.4A GB0412966D0 (en) 2004-06-10 2004-06-10 Genetically modified non-human mammals and cells
GB0412966 2004-06-10
PCT/GB2005/050086 WO2005120222A2 (en) 2004-06-10 2005-06-08 Genetically modified non-human mammals and cells

Publications (1)

Publication Number Publication Date
ES2535639T3 true ES2535639T3 (es) 2015-05-13

Family

ID=32732258

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05748982.5T Expired - Lifetime ES2535639T3 (es) 2004-06-10 2005-06-08 Células y mamíferos no humanos modificados genéticamente

Country Status (6)

Country Link
US (3) US8785717B2 (https=)
EP (1) EP1766033B1 (https=)
JP (1) JP2008501357A (https=)
ES (1) ES2535639T3 (https=)
GB (1) GB0412966D0 (https=)
WO (1) WO2005120222A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
EP1625166B1 (en) 2003-05-12 2015-04-08 Helion Biotech ApS Antibodies to masp-2
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2386316B1 (en) * 2004-06-10 2018-02-28 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN102781471B (zh) 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
EP2704743B1 (en) 2011-05-04 2020-03-11 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
CN112481302B (zh) * 2021-02-05 2021-05-14 百奥赛图(北京)医药科技股份有限公司 Masp2基因人源化的非人动物的构建方法及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
US7083786B2 (en) * 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7273925B1 (en) * 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
JP2003507338A (ja) 1999-08-13 2003-02-25 ザ ブリグハム アンド ウイメンズ ホスピタル インコーポレイテッド レクチン補体経路（ｌｃｐ）のインヒビターおよびその使用
AU2001261103B2 (en) * 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
NZ523900A (en) * 2000-07-13 2004-02-27 Jens Christian Jensenius Isolation and characterisation of a mannan-binding lectin (MBL) associated serine protease (MASP-2) and uses thereof to treat infections
US20020094332A1 (en) * 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
CA2454562A1 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals, Inc. Method of improving cognitive function
CA2473786A1 (en) 2002-01-22 2003-07-31 Alexion Pharmaceuticals, Inc. Method of prophylaxis against large myocardial infarctions
EP1570075A2 (en) * 2002-12-03 2005-09-07 Aarhus Universitet Method for determing predisposition to manifestation of immune system related diseases
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
AU2004216176B2 (en) * 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
EP1625166B1 (en) 2003-05-12 2015-04-08 Helion Biotech ApS Antibodies to masp-2
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005024013A1 (en) 2003-09-05 2005-03-17 Natimmune A/S Masp-2 crystal structure and uses thereof
WO2005123776A1 (en) 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
EP2386316B1 (en) 2004-06-10 2018-02-28 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation

Also Published As

Publication number Publication date
EP1766033B1 (en) 2015-01-28
JP2008501357A (ja) 2008-01-24
US20090205058A1 (en) 2009-08-13
GB0412966D0 (en) 2004-07-14
US8785717B2 (en) 2014-07-22
WO2005120222A3 (en) 2006-02-02
EP1766033A2 (en) 2007-03-28
US10660317B2 (en) 2020-05-26
US20150067897A1 (en) 2015-03-05
US20170127657A1 (en) 2017-05-11
WO2005120222A2 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
Boulday et al. Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis: implications for human cerebral cavernous malformations
ES2242437T3 (es) Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares.
Muro et al. Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan
ES2628867T3 (es) Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2
ES2524984T3 (es) Anticuerpos anti-globulómero a?, porciones de unión a antígeno de estos, hibridomas correspondientes, ácidos nucleicos, vectores, células huésped, métodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos, usos de dichos anticuerpos, y métodos para usar dichos anticuerpos
ES2535639T3 (es) Células y mamíferos no humanos modificados genéticamente
JP2019047818A5 (https=)
KR102538555B1 (ko) 항-트랜스티레틴 인간화 항체
ES2989499T3 (es) Modelo de roedor de xenoinjerto de amiloide derivado de paciente
Smith et al. Targeted disruption of cubilin reveals essential developmental roles in the structure and function of endoderm and in somite formation
Maroney et al. Tissue factor pathway inhibitor is required for cerebrovascular development in mice
Revert et al. Increased Goodpasture antigen-binding protein expression induces type IV collagen disorganization and deposit of immunoglobulin A in glomerular basement membrane
ES2716175T3 (es) Mamífero no humano transgénico para producir anticuerpos de inmunoglobulina E humanos quiméricos
Snyder et al. Expression of human tissue factor under the control of the mouse tissue factor promoter mediates normal hemostasis in knock-in mice
Bluteau et al. Targeted disruption of the intracellular domain of receptor FgfrL1 in mice
CN106994185B (zh) Tie2对视网膜及其他组织中静脉血管的保护作用及应用
KR101300777B1 (ko) 과산소 노출에 의한 폐손상 모델 동물, 및 ｔａｚ 마커를 이용한 과산소 노출에 의한 폐손상 진단용 키트
Petersen et al. A previously uncharacterized Factor Associated with Metabolism and Energy (FAME/C14orf105/CCDC198/1700011H14Rik) is related to evolutionary adaptation, energy balance, and kidney physiology
JP6870851B2 (ja) 機能的な一本鎖抗体の製造方法
Meng et al. Generation and identification of endothelial-specific Hrh2 knockout mice
Kumar et al. Transgenic overexpression of cardiac actin in the mouse heart suggests coregulation of cardiac, skeletal and vascular actin expression
US7700823B2 (en) Transgenic animals exhibiting major disorders related to Alzheimer's disease
JP5645357B2 (ja) サイトグロビン遺伝子の機能が欠損している非ヒト疾患モデル動物
Kugelmann et al. Dsg2 truncation causes a lethal barrier breakdown in mice
PT1670309E (pt) Animais transgénicos com distúrbios graves relacionados com a doença de alzheimer